Brief communication: attitudes and preferences of long-acting injectable HIV preexposure prophylaxis among Thai adolescents and young adults

被引：0
|
作者：
Wongsethanatada, Alisa [1 ]
Songtaweesin, Wipaporn Natalie [2 ,3 ]
Wongharn, Prissana [3 ]
Moonwong, Juthamanee [3 ]
Khamthi, Sasiprapha [3 ]
Pitikawinwong, Lucksanapon [3 ]
Puthanakit, Thanyawee [3 ,4 ,5 ]
机构：
[1] Chulalongkorn Univ, Fac Med, Bangkok, Thailand
[2] Chulalongkorn Univ, Fac Med, Sch Global Hlth, Bangkok, Thailand
[3] Ctr Excellence Pediat Infect Dis & Vaccines, Bangkok, Thailand
[4] Thai Red Cross Soc, King Chulalongkorn Mem Hosp, Bangkok, Thailand
[5] Chulalongkorn Univ, Fac Med, Dept Pediat, Div Infect Dis, Bangkok, Thailand
来源：
AIDS RESEARCH AND THERAPY | 2025年 / 22卷 / 01期
关键词：
HIV; PrEP; Long-acting; Youth; Adolescents; Men who have sex with men; Preference; CABOTEGRAVIR; PREVENTION;
D O I：
10.1186/s12981-025-00721-z
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
This study aimed to explore willingness to use and preference for long-acting injectable PrEP (LAI-PrEP) among Thai youth at risk of HIV. A cross-sectional study was conducted in 100 Thai youth aged 18 to 24 years attending a sexual health clinic in Bangkok, Thailand. Participants received information about oral and LAI-PrEP before completing a questionnaire. Of the 98 participants willing to use pre-exposure prophylaxis, 47 preferred the injectable form. Preference for the injectable form was higher among individuals not currently using oral pre-exposure prophylaxis, affordability and longer injection intervals were key for acceptance of long-acting injectable pre-exposure prophylaxis.
引用
收藏
页数：5
相关论文
共 50 条
  • [11] Assessing Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among Young Adult Sexual Minority Men and Transgender Women
    Weeden, Terrance
    Garofalo, Robert
    Johnson, Amy K.
    Schnall, Rebecca
    Scherr, Thomas
    Kuhns, Lisa M.
    Cervantes, Marbella
    ACADEMIC PEDIATRICS, 2024, 24 (07) : 1110 - 1115
  • [12] Who wants long-Acting injectable antiretroviral therapy? Treatment preferences among adults with HIV in Florida
    Fisk-Hoffman, Rebecca J.
    Liu, Yiyang
    Somboonwit, Charurut
    Widmeyer, Maya
    Canidate, Shantrel
    Prosperi, Mattia
    Cook, Robert L.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2024, 36 (11): : 1545 - 1554
  • [13] Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis
    Landovitz, Raphael J.
    Delany-Moretlwe, Sinead
    Fogel, Jessica M.
    Marzinke, Mark A.
    Piwowar-Manning, Estelle
    Richardson, Paul
    Halvas, Elias K.
    Mellors, John W.
    Persaud, Deborah
    Kofron, Ryan
    McCauley, Marybeth
    Rose, Scott
    Rinehart, Alex R.
    Rooney, James F.
    Adeyeye, Adeola
    Cohen, Myron S.
    Donnell, Deborah
    Hosseinipour, Mina C.
    Grinsztejn, Beatriz
    Eshleman, Susan H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (13) : 1253 - 1256
  • [14] A shot at equity? Addressing disparities among Black MSM in the coming era of long-acting injectable preexposure prophylaxis
    Goedel, William C.
    Nunn, Amy S.
    Chan, Philip A.
    Duncan, Dustin T.
    Biello, Katie B.
    Safren, Steven A.
    Marshall, Brandon D. L.
    AIDS, 2019, 33 (13) : 2110 - 2112
  • [15] Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis
    Prather, Caitlin
    Jeon, Chaeok
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (21) : 1898 - 1905
  • [16] High Retention and Adherence With Rapid Long-acting Injectable Preexposure Prophylaxis Implementation in an Urban Safety Net Clinic Population
    Spinelli, Matthew A.
    Bisom-Rapp, Ezra
    Heise, Megan J.
    Camp, Christina
    Appa, Ayesha
    Liu, Albert Y.
    Sassaman, Kevin
    Shiels, Mary
    Mayorga-Munoz, Francis
    Chimezie, Anthonia
    Nguyen, Janet
    Oskarsson, Jon
    Gandhi, Monica
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [17] Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis
    Ahluwalia, Amrit Kaur
    Inzaule, Seth
    Baggaley, Rachel Clare
    Vitoria, Marco
    Schaefer, Robin
    Schmidt, Heather-Marie Ann
    Rodolph, Michelle
    Giron, Amalia
    Jordan, Michael R.
    AIDS, 2022, 36 (13) : 1897 - 1898
  • [18] Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States A Cost-Effectiveness Analysis
    Neilan, Anne M.
    Landovitz, Raphael J.
    Le, Mylinh H.
    Grinsztejn, Beatriz
    Freedberg, Kenneth A.
    McCauley, Marybeth
    Wattananimitgul, Nattanicha
    Cohen, Myron S.
    Ciaranello, Andrea L.
    Clement, Meredith E.
    Reddy, Krishna P.
    Hyle, Emily P.
    Paltiel, A. David
    Walensky, Rochelle P.
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (04) : 479 - +
  • [19] Real-world Human Immunodeficiency Virus RNA and Antigen/Antibody Testing Among People Who Use Long-acting Injectable Preexposure Prophylaxis
    Zhu, Weiming
    Delaney, Kevin
    Huang, Ya-Lin A.
    Patel, Rupa R.
    Kourtis, Athena P.
    Hoover, Karen W.
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [20] Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV
    Simoni, Jane M.
    Beima-Sofie, Kristin
    Mohamed, Zahra H.
    Christodoulou, Joan
    Tapia, Kenneth
    Graham, Susan M.
    Ho, Rodney
    Collier, Ann C.
    AIDS PATIENT CARE AND STDS, 2019, 33 (03) : 104 - 111
12345